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a b s t r a c t
Free hemoglobin (Hb) triggered vascular damage occurs in many hemolytic diseases, such as sickle cell
disease, with an unmet need for speciﬁc therapeutic interventions. Based on clinical observations the Hb
and heme scavenger proteins haptoglobin (Hp) and hemopexin (Hx) have been characterized as a se-
quential defense system with Hp as the primary protector and Hx as a backup when all Hp is depleted
during more severe intravascular hemolysis. In this study we present a mechanistic rationale for this
paradigm based on a combined biochemical and cell biological approach directed at understanding the
unique roles of Hp and Hx in Hb detoxiﬁcation. Using a novel in vitro model of Hb triggered endothelial
damage, which recapitulates the well-characterized pathophysiologic sequence of oxyHb(Fe2þ) trans-
formation to ferric Hb(Fe3þ), free heme transfer from ferric Hb(Fe3þ) to lipoprotein and subsequent
oxidative reactions in the lipophilic phase. The accumulation of toxic lipid peroxidation products liber-
ated during oxidation reactions ultimately lead to endothelial damage characterized by a speciﬁc gene
expression pattern with reduced cellular ATP and monolayer disintegration. Quantitative analysis of key
chemical and biological parameters allowed us to precisely deﬁne the mechanisms and concentrations
required for Hp and Hx to prevent this toxicity. In the case of Hp we deﬁned an exponential relationship
between Hp availability relative to oxyHb(Fe2þ) and related protective activity. This exponential re-
lationship demonstrates that large Hp quantities are required to prevent Hb toxicity. In contrast, the
linear relationship between Hx concentration and protection deﬁnes a highly efﬁcient backup scavenger
system during conditions of large excess of free oxyHb(Fe2þ) that occurs when all Hp is consumed. The
diverse protective function of Hp and Hx in this model can be explained by the different target speci-
ﬁcities of the two proteins.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Hemoglobin (Hb) release from red blood cells (RBC) is a com-
mon pathophysiology of many disorders. Systemic hemolysis oc-
curs during certain genetic and acquired anemia, such as in sickle
cell disease and malaria. Localized Hb release occurs at conﬁned
sites of tissue injury, inﬂammation, or within atherosclerotic pla-
ques. Depending on the scale, rate, and site of hemolysis, the
primary adverse effects triggered by free Hb are vascular dys-
function, oxidative tissue damage, and altered inﬂammatory re-
sponse [1–6].
The Hb and heme scavenger proteins haptoglobin (Hp) and
hemopexin (Hx) exhibit high binding rate constants for Hb [7] and
heme [8], respectively. Both in vitro and in vivo studies have de-
monstrated the ability of these proteins to attenuate Hb and heme-
induced toxicity [9–11]. Under physiologic conditions Hp and Hx
exist at comparable plasma concentrations and both are depleted
from plasma after binding Hb or heme, respectively. However, in
patients with hemolysis Hp depletes early in the course of the
disease while levels of Hx remain within the physiologic range for
prolonged periods of sustained hemolytic disease [12]. Based on
these observations, the two proteins have been characterized as
constituents of a sequential Hb/heme protection system with Hp as
the primary defense and Hx as the backup, which provides pro-
tection against more severe Hb exposure once Hp becomes de-
pleted [12,13]. The biochemical basis of this paradigm of sequential
protection by Hp and Hx has yet to be explored systematically.
The vasculature is one of the principal targets of Hb toxicity [14].
Many studies have explored basic mechanisms of Hb or heme
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Fig. 1. Effects of combined treatment of rLP and Hb on human umbilical vein endothelial cells. A. Hierarchical two-way clustering analysis of whole genome expression
arrays. HUVEC where treated for 9 h with rLP (0.5 mg/ml), Hb (10 μM), or both. Only genes found to exhibit statistically signiﬁcant differential regulation by ANOVA are
shown. The clustering indicates clear separation of the treatment conditions with most pronounced gene expression changes for combined rLPþHb treatment. Details of
gene expression data can be found in the data supplement. B. Time course of cellular ATP depletion. The rLP (0.5 mg/ml)þHb (10 μM) triggered damage response in HUVEC
cells is prevented by Hp and Hx added at excess concentration over Hb (each at 15 μM heme-equivalent binding capacity). C. Principal component analysis of gene expression
proﬁles of untreated HUVEC or HUVEC treated with rLPþHb in the absence of any scavenger or with Hx or Hp of dimeric or multi-meric phenotype (Hp 1–1 and Hp 2–2). The
data conﬁrm that the HbþrLP triggered gene expression changes are prevented by Hx and Hp. The axes indicate principal components (PC1 and PC2). D. Electric cell-
substrate impedance sensing (ECIS) of HUVEC treated with rLP alone or in combination with heme, metHb (Fe3þ), or oxyHb (Fe2þ). rLP in combination with oxyHb leads to
disruption of endothelial monolayer integrity after about 10 h. If oxyHb is replaced by ferric Hb or free heme, the time to disruption is shortened to about 6 h. Single
treatment with heme, oxyHb or ferric Hb does not change monolayer integrity (not shown).
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triggered endothelial damage and have suggested that oxidative
reactions of Hb generate multiple toxic species such as free heme
that is released from ferric Hb, iron, free radicals, and globin ag-
gregation products [15–25]. Toxic reaction products such as oxi-
dized lipoproteins are formed in secondary reactions [19,26].
Therefore, the well-characterized sequence of Hb triggered en-
dothelial toxicity is a relevant pathophysiologic situation to quan-
titatively evaluate differential protective scavenger protein re-
quirements of Hp and Hx during Hb exposure.
Here we present a novel in vitro model of Hb-mediated en-
dothelial toxicity, which recapitulates the established sequence of
heme iron oxidation from ferrous Hb (Fe2þ) to ferric Hb (Fe3þ),
heme release from ferric Hb, and heme-driven oxidation of un-
saturated fatty acids as the critical mechanism driving Hb-induced
endothelial damage. Unlike previous studies that focus on in-
dividual contributions of Hp or Hx irrespective of concentration
dependence, within this global model we identiﬁed measures of
Hb/lipid oxidation and endothelial damage, which allowed us to
quantitatively deﬁne scavenger protein requirements of Hp and Hx
in relation to the amount of oxyHb (Fe2þ) present in the system.
Our data show that at least iso-stoichiometric quantities of the
primary scavenger Hp in relation to oxyHb (Fe2þ) are required to
provide full protection. In contrast, sub-stoichiometric quantities
of the backup scavenger Hx are sufﬁcient to signiﬁcantly attenuate
Hb triggered lipid oxidation and endothelial damage in the ab-
sence of Hp.
2. Materials and METHODS
2.1. Chemicals and concentrations
Puriﬁed Hb was further processed by DEAE ion exchange
chromatography to remove catalase and other antioxidant en-
zymes. After puriﬁcation Hb was in the oxyHb(Fe2þ) sate with no
detectable ferric Hb(Fe3þ). Throughout this article, molar quan-
tities of Hb relate to total heme, which is equivalent to the single
chain subunits of Hb (alpha or beta chain). For the scavenger
proteins (Hx and Hp), we considered one mole as the binding
capacity equivalent for one mole of heme, considering that one Hp
αβ-subunit (E42 kD) can bind two heme molecules (corre-
sponding to one αβ-dimer), while a Hx molecule (E57 kD) can
bind one heme molecule. Hb concentration was measured by
spectrophotometry using a molar extinction coefﬁcient of
524.3 M1 cm1 at an absorbance wavelength of 414 nm (for
oxyHb).
Ferric Hb (Fe3þ) was generated by incubating oxyHb (Fe2þ)
with a ﬁve times molar excess of K3[Fe(CN)6] in PBS, pH 7.45 at
room temperature for 10minutes followed by removal of
K3[Fe(CN)6] by size exclusion separation on a PD-10 column (GE
Healthcare). Ferric Hb concentration and complete oxidation
to ferric iron (Fe3þ) within Hb where then determined by
spectrophotometry.
Heme was dissolved in 5 ml DMSO at a concentration of 10 mM
and then 5 ml of 1 M NaOH was added. The solution was mixed
vigorously and then dissolved to a ﬁnal stock concentration of
1 mM with PBS. This stock solution was immediately frozen and
stored at - 20°C until use. Additional freeze-thaw cycles were
avoided.
Human plasma derived Hp (predominantly phenotype 2–2)
and Hx were provided by CSL Behring (Bern, Switzerland). For the
experiment shown in Fig. 1C we additionally used an Hp product
from BPL Bio Products Laboratories, which is predominantly phe-
notype 1–1. The purity of the proteins was analyzed by gel
electrophoresis (Supplemental Figure 1) and by LC-MSMS. The
irreversible Hb binding function of Hp was conﬁrmed by surface
plasmon resonance (SPR). Heme binding of Hx was conﬁrmed by
spectrophotometry, which shows a speciﬁc spectrum for the Hx-
heme complex [7]. Concentrations of binding-proteins were
measured by spectrophotometry at 280 nm using a molar extinc-
tion coefﬁcient of 25.8 mM1 cm1 for Hp and 116 mM1 cm1
for Hx.
Reconstituted lipoprotein (rLP; CSL-111) was obtained from CSL
Behring (Switzerland) [27]. rLP was reconstituted in PBS to a ﬁnal
stock concentration of 40 g/l and immediately aliquoted and
stored at 80 °C until use. For rLP, all given concentrations are
relative to the apoA1-lipoprotein concentration. The lipoprotein is
composed of human plasma derived apoA-I lipoprotein and le-
cithin with phosphatidylcholine as the principal lipid component.
2.2. Cell culture experiments
Human umbilical vein endothelial cells (HUVEC) were obtained
from Lonza (Switzerland) and cultured in EGM medium (Lonza)
under standard conditions. All experiments were conducted in
complete EGM without ascorbic acid with cells forming a con-
ﬂuent monolayer.
2.3. Gene expression microarray experiments and data analysis
RNA preparation and quality control was performed as re-
ported earlier [28]. Fluorescently labeled cRNAwas generated from
500 ng total RNA using the Quick Amp Labeling Kit (Agilent
Technologies, Basel, Switzerland) according to the manufacturer's
protocol, and differential gene expression proﬁling was performed
by competitive dual-color hybridization on Whole Human Gen-
ome Oligo Microarrays (G4845A, 444K, 60-mer, Agilent Tech-
nologies). Array slides were XDR scanned and analyzed with
Feature Extraction Software Version 10.7.3.1 (Agilent Technolo-
gies). Statistical analysis and visualization were performed with
JMP Genomics 5.0 (SAS). Speciﬁed clusters of regulated genes were
analyzed for enrichment of functional networks by using Metacore
analysis software (Thomson Reuters).
2.4. Electrical cell impedance sensing (ECIS) and ATP measurement
Conﬂuent HUVEC cells grown in one 10- cm tissue culture plate
were trypsinized and plated into two 8W10Eþ ECIS plates ﬁlled
with 400 ml medium per well. Cells were allowed to settle for 24 h,
and then the medium was changed to 300 ml per well. After 2–5 h,
when the ECIS-signal stabilized, 100 ml of pre-warmed 4x treat-
ment was added directly to the wells while running the ECIS ac-
quisition at 4 kHz. The signal was then normalized to 30 min be-
fore treatment. The amount of time required to lose endothelial
monolayer integrity was calculated by ﬁnding the minimum in the
ﬁrst derivate of the measured resistance over time.
Cellular ATP was measured with a chemiluminescent assay
(CellTiter-Glos Assay, Promega AG, Dubendorf, Switzerland). Ex-
periments were performed in 96-well plates, and luminescence
was measured with an Inﬁnite M200-Pro plate reader (Tecan
Group Ltd., Männedorf, Switzerland).
2.5. Spectrophotometry
Experiments were conducted in 1 ml semi-micro cuvettes at
37 °C using a Cary 60 spectrophotometer (Agilent, Switzerland).
Absorbance was measured over time at every 2 nm between 350
to 650 nm with a 0.025 s integration time per wavelength. Spectra
were deconvoluted against standard extinction curves of the pure
substances using a non-negative least squares algorithm. The time
to oxygen depletion was calculated as the minimum of the ﬁrst
derivative of the oxyHb concentration over time.
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2.6. Simultaneous oxygen concentration measurement during
spectrophotometry
rLP was incubated at 0.5 g/l in PBS, pH 7.45 with 10 mM oxyHb
at 37 °C. Oxygen content was measured with an O2 microsensor
placed directly in the spectrophotometry cuvette and recorded
with SensorTrace Pro Software (both from Unisense, Aarhus,
Denmark). Oxygen sO2 was calculated for the measured oxygen
concentration using the Kelman [29] formula adjusted for a pCO2
of 0.
2.7. Measurement of thiobarbituric acid reactive substances (TBARS)
A 100 ml aliquot of the sample was diluted in 500 ml of 750 mM
trichloracetic acid in 1 M HCl. After vortexing, 400 ml of a 25 mM
solution of 2-thiobarbituric acid in 1 M NaOH was added and then
the sample was incubated for 60 min at 80 °C. After pelleting
debris, TBARS were quantiﬁed in the supernatant. For absolute
quantiﬁcation, the absorption at 532 nm (thereof subtracted the
absorption at 600 nm) was used to calculate the concentration
with the extinction coefﬁcient of 0.156 mM1 cm1 using a 1- cm
pathlength cuvette. For a more sensitive but relative quantiﬁca-
tion, we measured the ﬂuorescence emission at 590 nm using
540 nm as the excitation wavelength.
2.8. Detection of 4-hydroxynonenal protein adducts be Western blot
rLP (0.5 g/l) with or without Hb (50 mM), Hx (10 mM) or Hp
(10 mM or 50 mM) was incubated for 120 min at 37 °C in PBS pH 7.4.
The reaction was stopped by addition of the same volume of
Lämmli-Buffer containing 5% beta-mercaptoethanol, samples were
boiled for 5 min at 95 °C, spun down and 10 ml per lane run on a
Criterion Any-KD Stain-Free gel (Bio-Rad). The gel was activated
during 1 min under UV-Light and then blotted onto a PVDF-
Membrane. After blocking with PBS containing 10 g/l BSA, 10%
goat-serum and 0.1% Tween-20 over night, the mouse monoclonal
anti-hydroxynonenal-antibody (MAB3249, RD-Systems) was in-
cubated for 1 hour at 1 mg/l concentration followed by an Alexa-
Fluor-660 anti-mouse IgG antibody (Life Technologies) for another
hour. The blot was visualized on a Chemidoc MP imager (Bio-Rad).
2.9. Lipid Mass Spectrometry (LMS)
0.5 g/l rLP was reacted with Hb for 2 h at 37 °C (oxidized rLP).
As a control, rLP was incubated under the same conditions in the
absence of heme (non-oxidized rLP). To extract the lipids, we used
a modiﬁed method based on Matyash [30]. Brieﬂy, 200 ml of each
sample was added to 1.5 ml of methanol containing 50 mg/l bu-
tylated hydroxytoluene (BHT) in a 15 ml borosilicate glass test
tube. After mixing, 5 ml of methyl tert-butyl ether was added and
extracted for 60 min at room temperature by vigorous shaking
followed by the addition of 1.25 ml of water and incubation for
another 10 min. After centrifugation at 1,000 g for 10 min, the
upper phase was transferred to a new glass tube and dried under a
steady ﬂow of nitrogen at 37 °C. The dry lipid pellet was re-sus-
pended using 0.5 ml of methanol and agitated for 20 min. Samples
were then stored at 4 °C in 2 ml amber glass vials (SUPELCO,
Bellefonte, PA, USA) until the next step. Immediately before mass
spectrometric analysis, lipids were diluted 1:5 in a solution con-
taining 10 mM ammonium acetate in 80% methanol and analyzed
by reverse phase chromatography on a Q-Exactive mass spectro-
meter (Thermo Fisher Scientiﬁc, Bremen, Germany) coupled to a
nanoACQUITY UPLCs system (Waters, Milford, MA, USA). Lipids
were automatically selected by an auto-sampler and successively
separated on a 5 cm-long fused silica emitter column (200 mm i.d.;
BGB Analytik, Boeckten, Switzlerand) and in-house packed with
HSS T3, 100 Å, 1.8 mm, C18 resin (Waters). The chromatographic
separation was performed using a 2-propanol:ACN/water solvent
system containing 5 mM ammonium acetate at a ﬂow rate of 2 ul/
min. A gradient from 2% to 98% 2-propanol:ACN in 10minutes was
used. The total run time was 22 min, which also included sample
injection and column equilibration. Mass spectra were acquired in
a data-dependent manner with an automatic switch between MS
and MS/MS using a top 5 method. MS spectra were acquired using
the Orbitrap analyzer with a mass range of 80–1200 m/z and
70,000 resolution at m/z 200. HCD lipid fragments were obtained
using a stepped normalized collision energy of 20–30 with an AGC
target value of 5104 at 17,500 resolution. The isolation window
was set to 0.4 Da. Dynamic exclusion (710 ppm tolerance) was
used with one repeat count and a 6 s exclusion duration. Mea-
surements were performed using an internal lock mass calibration
on m/z 371.10124 and 445.12003. Chromatograms of selected MS1
ions were extracted using Xcalibur software (Thermo Fisher Sci-
entiﬁc, USA). Comparative m/z-RT plots were generated by align-
ing two images produced using the Pep3D software (TPP, Seattle
Proteome Center) by FIJI (www.ﬁji.sc).
2.10. Statistical analysis
Unless otherwise indicated, all statistical analyses, model gen-
eration, and ﬁtting were performed using the R statistical software
(www.r-project.org).
3. RESULTS
3.1. An in vitro model of Hb lipoprotein-triggered endothelial toxicity
Hb is a known oxidizer of lipoprotein (LP) [6]. Oxidized LP (ox-
LP) then induces toxic effects in endothelial cells [6]. Because of
the variability of lipid and intrinsic anti-oxidant composition in
plasma-derived LP, previous models of Hb triggered lipid oxidation
have used free heme (a stronger oxidant), bolus addition, or in situ
enzymatic generation of H2O2 to produce a sufﬁciently strong
oxidative drive to overcome the unpredictability of oxyHb (Fe2þ)
oxidative reactions [16,18,19,21]. These systems have clear lim-
itations for the modeling of scavenger protein effects during he-
molytic conditions, which are always characterized by an excess of
ferrous Hb with relatively mild oxidative stress [9]. The in vitro
model presented herein, replaces natural LP with a reconstituted
lipoprotein (rLP) composed of apoA-I lipoprotein, which serves as
a stabilizer of the LP particle, in conjunction with a deﬁned lipid
component composed of saturated and unsaturated fatty acids in
the form of phosphatidylcholine (PC), absent anti-oxidants. We
hypothesized that this rLP lipid component would react sponta-
neously and more predictably with ferrous Hb to produce oxidized
LP (ox-LP) and Hb oxidation products and then eventually yield
toxic end-products.
Fig. 1A shows results from a whole genome microarray analysis
that was performed on human umbilical vein endothelial cells
(HUVEC) treated with 0.5 g/l rLPþ10 mM oxyHb(Fe2þ) or either
compound alone. Gene array data are accessible at NCBI’s Gene
Expression Omnibus under http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc¼GSE66283 and in the data supplement. Hier-
archical clustering analysis demonstrates that dramatic changes in
gene expression were induced by combined treatment with rLP
and Hb in complete culture medium compared to the individual
compounds. In particular, 286 transcripts were up-regulated by
rLPþoxyHb (Fe2þ), while 371 were down-regulated. A Metacores
gene enrichment analysis for biological processes suggested acti-
vation of the response to unfolded proteins and apoptosis trig-
gered by the MAPK and JAK/STAT pathways. This gene expression
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response was associated with a decrease in cellular ATP (Fig. 1B).
Both, the gene expression response and the drop in cellular ATP
were completely blocked by Hp and Hx when added in excess over
heme concentration (Fig. 1B/C). rLPþHb disrupted the endothelial
barrier integrity, measured by ECIS, within 12hours. In contrast,
exposure to either rLP or Hb alone did not change endothelial
resistance (Fig. 1D). Compared to the effect of oxyHb (Fe2þ) the
cytotoxic effect of rLPþHb was accelerated to approximately twice
the rate following replacement of oxyHb (Fe2þ) with ferric Hb
(Fe3þ). Identical acceleration was observed when ferric Hb (Fe3þ)
was replaced by an iso-stoichiometric amount of free heme, in-
dicating that the globin component of Hb is not directly involved
in the cytotoxic response in this model. No signiﬁcant effect on
endothelial barrier integrity was observed when the cells were
incubated with ferric Hb(Fe3þ) or heme alone. These data are
supported by immunoﬂuorescence staining for β-catenin, which
demonstrate disintegration of endothelial adherence junctions
following treatment with either rLPþoxyHb (Fe2þ), rLPþferric Hb
(Fe3þ) or rLPþheme. These effects were blocked by the addition of
excess concentrations of Hp and Hx (Fig. 2).
3.2. Biochemical characterization of the Hb-lipoprotein reaction
Using spectrophotometry combined with spectral deconvolu-
tion, we evaluated the dynamic changes in Hb oxygenation and
heme-iron redox states that occurred when 10 μM oxyHb (Fe2þ)
was reacted with 0.5 g/l rLP (Fig. 3A). The aim of these initial bio-
chemical experiments was to deﬁne key parameters for quantitative
characterization of the cytoprotective effects of Hp and Hx in later
experiments. During the reaction, conversion from oxyHb to
deoxyHb occurred after 20 min. Around this time point, the con-
centration of ferric Hb (Fe3þ) and ferryl Hb (Fe4þ) increased. These
data are suggestive of an oxygen-consuming reaction characteristic
of singlet oxygen (1O2)-mediated lipid oxidation. The time-point at
which Hb became desaturated was used in subsequent experiments
as a marker of the reaction velocity and its modulation. To verify the
spectral deconvolution data, we measured the oxygen consumption
rate during the reaction with a Clark-type electrode and calculated
Hb oxygen saturation (sO2) (Fig. 3B). sO2 calculated from the mea-
sured oxygen concentration and by spectrophotometry showed
very similar results, demonstrating the accuracy of our spectro-
photometric method for monitoring oxygen consumption by the
rLP-Hb reaction.
Accumulation of rLP-derived lipid oxidation products was
conﬁrmed by LC-MS/MS. Fig. 4A shows a representative 2D plot of
retention time versus m/z with an in silico overlay of a control rLP
sample and an rLP sample that was treated with oxyHb for 8 h at
37 °C. In this overlay, white indicates the products present in both
samples, while magenta represents products of the rLP-Hb reac-
tion. The appearance of magenta species with progressively higher
m/z and lower retention time (¼higher polarity) is compatible
with the generation of multiple lipid oxidation products that are
characterized by serial oxygen adduction.
To conﬁrm this hypothesis, we identiﬁed within the dataset
speciﬁc phosphatidylcholines (PC), which constitute the major
component of rLP, and searched for putative oxidized forms of
these lipids. The structural formula of an exemplary poly-
unsaturated PC (1-octadecatrienoyl-2-octadecenoyl-sn-glycero-3-
phosphocholine) is depicted in Fig. 4B. The single-ion trace of the
non-oxidized PC present at the onset of the reaction was extracted
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Fig. 2. Hp and Hx prevent endothelial adherence junction disruption induced by rLPþHb treatment. Immunoﬂuorescence images of HUVEC stained for β-catenin (yellow,
Alexa-555 ﬂuorescence). HUVEC were treated for 6 h with rLP alone (control) or rLPþoxyHb,þmetHb, orþheme in the absence or presence of Hx or Hp. Note the spiculated
pattern of beta-catenin staining in all treatments including unprotected heme or Hb.
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and plotted versus retention time (Fig. 4C, black trace). A series of
oxygen adduction products of this PC, which are deﬁned by
characteristic mass (15.9949 u¼þ1 oxygen) and retention time
shifts (increased polarity), were identiﬁed (colored traces) along
with the non-oxidized precursor PC in the rLPþHb reaction. These
oxidized forms were not present in the rLP prior to Hb triggered
oxidation.
From the previous experiments, it was unclear whether endothelial
changes following rLPþHb exposure in our model were caused by
oxidized rLP species, free heme, or mechanisms that involved short-
lived reaction intermediates such as free radicals or ferryl iron (Fe4þ).
Only toxicity due to globin oxidation products could be excluded
because Hb could be replaced with heme (as shown in Fig. 1D).
Therefore, to identify the cytotoxic species, we incubated endothelial
cells with rLP that had been pre-reacted with heme and then depleted
of free heme immediately prior to cell exposure by addition of excess
Hx (Fig. 4D). The immediate cytotoxicity of this reaction product,
which occurred without the typical lag-time, suggests that the accu-
mulated lipid oxidation products are the ultimate mediator of toxicity.
As a control, endothelial cells were treated with rLP that was in-
cubated with hemeþHx throughout the experiment including the
pre-incubation period. Due to the irreversible binding of Hx to heme,
lipid oxidation did not occur and cytotoxicity was not observed.
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3.3. Free heme transfer from ferric Hb (Fe3þ) into rLP
Next, we performed studies to identify the reaction intermediates
that promote rLP oxidation in our model following the addition Hb.
Fig. 5A illustrates that addition of free heme to the oxyHb (Fe2þ)þrLP
reaction accelerates oxygen consumption, which is observed by a
shorter time to tdesaturation. Addition of equimolar amounts of ferric Hb
(Fe3þ) yielded identical results as addition of free heme. Ferric Hb
Fig. 4. The rLPþHb reaction generates toxic lipid oxidation products. A. Overlay of two m/z x retention time plots of all compounds that were detected by LC-MSMS in native
rLP (cyan) and heme-treated rLP (magenta). Compounds appearing cyan were more abundant in the native rLP sample whereas compounds appearing magenta were more
abundant in the Hb-treated sample. Compounds appearing white were found in both samples. The right shifted population (increased m/z) of magenta colored compounds
in the rLPþHb samples is compatible with oxidation (oxygen adduction, increased mass). The y-axis is the retention time, where more polar (i.e. oxygen adducted/ oxidized
compounds in the rLPþHb sample) compounds are further down (lower retention time) and more apolar, lipophilic substances are further up (higher retention time). The
dashed lines to panel C indicate the area where the main intensity peak of the single-ion chromatograms shown in Fig. 4C were located. Overall the right/down shifted cloud
of compounds in the rLPþHb samples is compatible with extensive oxidative lipid modiﬁcations. B. Structure of the exemplary phosphatidylcholine 1-octadeca-2,4,6-
trienoyl-2-octadeca-11-enoyl-sn-glycero-3-phosphocholine PC(18:3[2,4,6]/18:1[11]) in its unoxidized form. C. Single-ion chromatograms of native and oxygen adducted PC
(18:3[2,4,6]/18:1[11]) extracted from native and Hb reacted rLP, respectively. The native lipid is shown in black ([M-H]- ion), while all other ions (colored traces) are depicted
as putative oxidized species identiﬁed by an increase in m/z by one oxygen mass and decrease in retention time to increased polarity. The most oxidized species were
exclusively detected in Hb treated rLP. D. ECIS experiment measuring endothelial monolayer integrity of conﬂuent HUVEC treated with heme-catalyzed lipid peroxidation
products. Cells were treated with rLP that was pre-incubated with heme for 24 h and then captured with Hx to remove remaining free heme (red). As a control, cells were
treated with rLP incubated with heme that was already captured with Hx during the whole pre-incubation period (blue).
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may therefore be considered as a free heme donor in this system
(Fig. 5B). In another set of reactions, we replaced oxyHb (Fe2þ)
stepwise with ferric Hb (Fe3þ), while keeping the total heme content
constant throughout the reaction. Oxygen consumption, and thus rLP
oxidation, was accelerated relative to the proportion of replaced
oxyHb (Fig. 5C). In contrast, if the oxyHb (Fe2þ) concentration was
reduced without replacement by ferric Hb (Fe3þ), the oxygen con-
sumption and rLP oxidation rates became slower (Fig. 5D). These data
further conﬁrm that free heme is the catalyst of lipid peroxidation
while ferric Hb (Fe3þ) acts as a donor of free heme. The reaction rate
for Hb triggered ox-rLP formation is not determined by the con-
centration of oxyHb (Fe2þ), which is the primary species released
from red blood cells, but by the concentration of releasable heme in
ferric Hb (Fe3þ).
Further studies with lipophilic and hydrophilic radical sca-
vengers suggested that the ultimate heme-lipid peroxidation re-
action occurs in the lipid compartment of our system. Ascorbic
acid, which only acts in the aqueous phase due to its hydrophilic
functional groups, slowed the reaction, but did not inhibit it
completely. In contrast, butylated hydroxytoluene (BHT), a non-
polar lipophilic radical scavenger that accumulates exclusively in
the rLP spheres, completely stopped the Hb-rLP reaction (Fig. 5E).
The protection provided by Hx is a speciﬁc biochemical func-
tion of this protein since the low-afﬁnity heme scavenger albumin
and non-heme-binding immunoglobulin demonstrate minimal to
no effect on the oxidative reaction (Fig. 5F).
3.4. Quantitative analysis links target speciﬁcities of Hp and Hx to
different stoichiometric requirements for protection
In a next set of experiments we quantitatively assessed the
protective effects provided by the two scavenger proteins Hp and
Hx when they were present in the lipid oxidation system at sub-
stoichiometric concentrations relative to Hb. Hp slowed the rate of
oxygen consumption and prevented endothelial monolayer disin-
tegration. However, near stoichiometric concentrations of Hp re-
lative to heme were required for attenuation of these biochemical
and cellular changes (Fig. 6A, B). The mechanism of this protection
is likely related to the structural stabilization of Hb within the
complex, which prevents release of catalytically active heme in
case the Hb:Hp complex may be transformed to ferric Hb (Fe3þ).
The observation that near iso-stoichiometric Hp is required for
protection can be explained by the lack of speciﬁcity of this sca-
venger for free heme (or ferric Hb) binding. Instead, the effect of
Hp reduces the quantity of cumulative oxyHb (Fe2þ) and ferric Hb
(Fe3þ) in the system and prevents heme loss from the bound ferric
Hb fraction or when oxyHb:Hp complexes are converted to ferric.
To further demonstrate this assumption we stepwise replaced of
oxyHb (Fe2þ) in the reaction with Hb:Hp complexes while keeping
the total heme concentration in the reaction constant (Supple-
mental Figure 1). These data conﬁrm that the protection provided
by addition of Hp equals the effect that can be observed by de-
creasing the oxyHb (Fe2þ) equivalents.
In contrast to Hp, Hx prolonged the time to oxygen depletion
even at low (sub-stoichiometric) concentrations. In this case the
time to Hb desaturation was linearly proportional to the Hx
concentration (Fig. 6A). Moreover, Hx demonstrated a dose de-
pendent protection of endothelial monolayer integrity (Fig. 6B).
These experiments conﬁrm that in states of oxyHb excess where
a slow conversion to ferric Hb (Fe3þ) occurs, small amounts of Hx
can effectively remove heme from the system. The major de-
terminant of the protective capacity in this case is not the release
of Hb from red blood cells but the oxidation of oxyHb (Fe2þ) to
ferric Hb (Fe3þ).
Cumulatively, our data suggest that the different target speci-
ﬁcities of Hp and Hx determine their stoichiometric requirements
when added to a complex system with Hb-triggered lipid perox-
idation reactions and downstream cytotoxicity. As a ﬁnal experi-
mental illustration of this concept, we measured the accumulation
of thiobarbituric acid reactive substances (TBARS) following reac-
tion with ﬁxed concentrations of rLP (0.5 g/L), Hp (10 μM), Hx
(5 μM), and HpþHx (10 μMþ5 μM) along a oxyHb
concentration range of 0–100 μM. This experimental design en-
abled evaluation of the pro-oxidant effects of sub-stoichiometric to
supra-stoichiometric Hb concentrations relative to the scavenger
proteins (Fig. 7A). In the absence of either Hp or Hx, TBARS for-
mation was dependent solely on the amount of Hb present in the
reaction. Addition of Hp completely blocked lipid peroxidation
until the Hb concentration exceeded a 1:1 (Hb:Hp) stoichiometry.
Above this concentration threshold, when Hp was saturated,
TBARS formation followed an Hb dose-response curve that was
identical to the control reaction, which lacked Hp. In contrast, Hx
inhibited TBARS formation up to a 11-fold molar excess of oxyHb
(Fe2þ), demonstrating its ability to effectively remove heme from
the reaction at sub-stoichiometric concentrations relative to Hb. If
both Hp and Hx were added to the reaction simultaneously, the
effect of Hx on TBARS formation was extended exactly by the
concentration of Hp, indicating that Hx activity was spared until
the point at which Hp became saturated.
In an identical experiment as shown above we investigated
whether the speciﬁc lipid peroxidation product 4-hydro-
xynnonenal (4-HNE) is generated during the Hb reaction with rLP.
Fig. 7B shows a Western blot for 4-HNE alongside a total protein
stain. The experiment shows that a range of heterogeneous 4-HNE
protein-adducts are produced in the reaction of oxyHb(Fe2þ)
(50 μM) with rLP (0.5 g/L), while the protein components of Hb
and rLP (ApoA1) disappear, presumably as a result of protein
crosslinking and lipid peroxide adduction. In agreement with the
TBARS experiments, substoichiometric heme binding quantities of
Hx (10 μM) prevent these reactions, while higher heme-binding
equivalent concentrations of Hp (50 μM) are required to have the
same protective effect.
4. Discussion
In this paper, we provide a biochemical model that rationalizes
the role of Hp as a primary protection system, which controls all
adverse activities of free Hb. Once Hp is depleted, Hx functions as a
backup protection system providing sustained control of Hb-dri-
ven oxidative damage (Fig. 7B). These results are consistent with
and provide a mechanistic rationale for the observations of a se-
quential depletion pattern observed for these two scavenger pro-
teins in patients with hemolytic conditions [12,31].
To support the hypothesis that different stoichiometric re-
quirements for oxidative protection by Hp and Hx mediate their
global role as primary and backup control systems, we developed
an in vitro model that allowed us to quantify, compare, and
correlate the biochemical activity and endothelial protective ca-
pacity of the two scavenger proteins. In contrast to earlier mod-
els, including our own model of Hb oxidation and endothelial
damage [21], this new model is driven by a reaction of oxyHb
(Fe2þ) with a biochemically deﬁned lipoprotein in the absence of
additional oxidants such as H2O2. This model may be more re-
ﬂective of most conditions associated with hemolysis, in which
only a small fraction of the total oxyHb that is released from er-
ythrocytes is slowly transformed from the oxyHb (Fe2þ) state
into ferric Hb (Fe3þ) by autoxidation or reaction with oxidants
such as NO [9]. Only this small fraction of Hb (Fe3þ) can release
its heme and eventually trigger lipid oxidation and endothelial
damage. This pathophysiologic sequence with heme as the
ultimate trigger of lipid oxidation provides the basis for our
J.W. Deuel et al. / Free Radical Biology and Medicine 89 (2015) 931–943940
observation that the heme speciﬁc scavenger Hx is functional to
prevent heme toxicity in experimental conditions with vast ex-
cess of oxyHb (Fe2þ). Hp can also limit free heme availability by
its function as a structural stabilizer of the Hb molecule, which
blocks heme-release. However, Hp lacks speciﬁcity for the oxi-
dative active component (i.e. ferric Hb or free heme), which is
reﬂected by the high concentrations of Hp relative to Hb that
were required in our model to effectively block the toxic cascade.
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Fig. 7. Quantitative requirements differ between Hp and Hx for the prevention of lipid peroxidation. A. In this experiment 0.5 g/l rLP was incubated with a range of oxyHb
concentrations for 120 min at 37°C in PBS pH 7.4 in the absence or presence of Hp (10 μM heme-binding equivalent), Hx (5 μM heme-binding equivalent) or both scavengers.
TBARS where measured at 590 nm ﬂuorescence (excited at 540 nm). B. Western blot for 4-HNE (red ﬂuorescence channel). Total protein is shown in the green ﬂuorescence
channel. 1: (only 0.5 g/L rLP), 2: (rLPþ50 μM Hb), 3: (rLPþ50 μM Hbþ10 μM hemopexin), 4: (rLPþ50 μM Hbþ10 μM haptoglobin), 5: (rLPþ50 μM Hbþ50 μM haptoglobin).
C. Schematic of the different protective mechanisms provided by Hp and Hx relative to their stoichiometry. (a) oxyHb depletes NO, which causes vasoconstriction and a
hypertensive response. Autooxidation and reaction with NO and other oxidants convert oxyHb to metHb (step 1). (b) metHb triggers oxidative toxicity by heme release (step
2). (c) As long as enough haptoglobin is available to associate with extracellular Hb, both toxicity mechanisms are blocked and Hb toxicity is prevented. Once Hb exceeds the
Hp concentration, heme can be released from even small quantities of unbound ferric Hb (step 3) to induce oxidative toxicity. (e) In contrast to Hp, Hx forms complexes with
free heme (step 4) without any signiﬁcant consumption by the excess oxyHb. Hx is therefore able to delay oxidative Hb toxicity even during conditions with massive Hb
release that exceeds the concentrations of scavenger proteins.
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Our data demonstrate that protective functions were linked to
Hx concentration with a linear function. This linear relationship
explains the observation that Hx signiﬁcantly delays the toxic ef-
fects of heme even at sub-stoichiometric concentrations relative to
oxyHb. Conversely, the biochemical role of Hp within this context
correlated to Hb concentration in an exponential manner, sup-
porting the requirement of 1:1 stoichiometric concentrations of
Hp relative to Hb (Fe2þ) for effective modulation of lipid perox-
idation and attenuation of endothelial damage.
The differential quantitative requirements of Hp and Hx for
effective control of lipid peroxidation were also conﬁrmed in a
second model in which the accumulation of lipid peroxidation
products (TBARS and 4-HNE adducts) was directly quantiﬁed as a
function of the Hb to scavenger protein ratio (Fig. 7A) instead of
the time period to the appearance of predeﬁned markers of lipid
oxidation and endothelial damage. In these experiments we de-
monstrate that Hx prevented TBARS formation when Hb con-
centrations exceed the concentration of the scavenger by more
than ten-fold. In contrast, because Hp's mode of action simply
“reduces” the amount of Hb that could potentially release its heme
moiety after Hb (Fe3þ) transformation by exactly the fraction
bound in the Hb:Hp complex, Hp could not block lipid peroxida-
tion beyond Hb concentrations exceeding the binding capacity of
Hp.
When both Hp and Hx were present in the system, we ob-
served a right-shift of the TBARS formation curve that corre-
sponded exactly to the heme equivalent binding capacity of added
Hp. This observation supports another important aspect of the
sequential protection-depletion model. During free Hb exposure,
the Hb-heme stabilizing function of Hp provides not only a ﬁrst-
line of protection against Hb-triggered lipid peroxidation, but it
also supports that Hx is spared until the capacity of the primary
protection system is exhausted.
The sequential Hb scavenger protein protection-depletion
model allows for an adapted control of Hb adverse effects in
different disease conditions with varying activity and duration of
hemolysis [1]. In conditions with mild hemolysis or during short
episodes of acute hemolysis, Hp can control Hb vasoactivity 
which is driven by oxyHb(Fe2þO2) mediated NO depletion  in
addition to the prevention of renal Hb ﬁltration, and oxidative
tissue damage. However, this control of Hb toxicity comes at the
cost of very high scavenger consumption that can cause Hp de-
pletion within hours. The backup scavenger, Hx, cannot control
vasoactivity and extravasation of Hb. However, a limited quantity
of Hx provides prolonged control of heme-triggered oxidative
tissue damage (Fig. 7B) [11]. The endocytic recycling of apo-Hx by
liver cells may further support the prolonged protection provided
by Hx when Hp is depleted [32]. In contrast, Hp is degraded by
macrophages after endocytosis of the Hb:Hp complex by the
macrophage scavenger receptor CD163 [33]. The heme defense
role of Hx is also supported by other lower afﬁnity heme-binding
plasma proteins, which may either serve as a temporary reservoir
for free heme before it is neutralized by Hx, or which may pro-
vide a third line of defense when all Hx is consumed. Such al-
ternative heme-binding proteins are albumin (Kd) 108 M [34]
and a1-microglobulin (Kd.106M) [35]. In contrast, the hex-
acoordinate high afﬁnity heme-binding by Hx has a Kdo1013M
[36].
Hp and Hx are being considered as therapeutics for various
hemolytic conditions. While the biochemical functions of the two
proteins are broadly overlapping in certain disease models [3], the
principles of our model, designed to understand the combined
functional contribution of each scavenger in Hb/heme detoxiﬁca-
tion, may help guide selection of the most appropriate scavenger
for future experimental and/or hemolytic disease state speciﬁc
clinical studies. For example, administration of Hp at large doses
that match the quantity of Hb release may be the preferred ther-
apy for treating acute, intense episodes of intravascular hemolysis.
During acute hyperhemolysis, Hp may provide the most effective
approach to limiting kidney and cardiovascular system injury.
However, the requirements of Hp are considerable. For examples,
the total endogenous pool of plasma Hp of an adult person is about
3 g. This amount of Hp may only neutralize about 0.5% of the total
RBC Hb, which indicates that even supplementation of 10-fold the
endogenous Hp may neutralize no more than an amount of Hb
corresponding to acute hemolysis of 5% of total RBC. In patients it
may, therefore, not be possible to supplement protective Hp
plasma concentrations for prolonged periods in chronic hemolytic
states, such as in patients with sickle cell disease. Under these
conditions, regular administration of limited doses of Hx may al-
low sustained and selective protection against pro-oxidant-medi-
ated tissue injury. Estimating effective therapeutic doses is much
more difﬁcult for Hx than for Hp, because Hx requirements will
not be directly related to the rate of hemolysis but much more to
the rate of in vivo transformation of ferrous to ferric Hb as well to
the kinetics of Hx recycling. However, the general concept that
different quantities of the two scavenger proteins may provide
differential protection in hemolytic conditions has already found
experimental support in recent animal studies. For example, re-
peated administration of low doses of Hx (1 mg per animal/week)
to sickle cell mice was effective in attenuating vascular oxidative
damage [11]. In contrast, large single bolus doses of Hp were re-
quired in other studies to attenuate the acute renal and vascular
toxicity that emerged after transfusion of stored blood with acute
intravascular release of free Hb in large quantities [9].
In conclusion, we provide an experimental model that links the
roles of Hp and Hx as primary and backup protection systems with
the speciﬁc quantum requirement of each scavenger protein to
effectively control free Hb-triggered oxidative damage.
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